References of "Henrotin, Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAnalgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Sahebkar, A; Henrotin, Yves ULg

in Pain Medicine : The Official Journal of the American Academy of Pain Medicine (in press)

Background. Curcuminoids are natural products with potent anti-inflammatory and antioxidant properties. There have been a number of reports on the analgesic effects of curcuminoids in clinical trials, yet ... [more ▼]

Background. Curcuminoids are natural products with potent anti-inflammatory and antioxidant properties. There have been a number of reports on the analgesic effects of curcuminoids in clinical trials, yet data have not been fully conclusive. Objectives. To provide the highest level of evidence on the efficacy of curcuminoids in patients with painful conditions through meta-analysis of data from randomized controlled trials (RCTs). Methods. A systematic review and meta-analysis was conducted using data reported by RCTs. The primary efficacy measure was pain intensity or algofunctional status. Treatment effect was summarized with standardized mean difference (SMD) calculated from differences in means of pain measures between treatment and control groups using a random-effects model. Results. A total of eight RCTs met our inclusion criteria that included 606 randomized patients. Curcuminoids were found to significantly reduce pain (SMD: −0.57, 95% CI: −1.11 to −0.03, P = 0.04). This pain-relieving effect was found to be independent of administered dose and duration of treatment with curcuminoids, and was free from publication bias. Curcuminoids were safe and well tolerated in all evaluated RCTs. Conclusion. Curcuminoids supplements may be a safe and effective strategy to improve pain severity, by warranting further rigorously conducted studies to define the long-term efficacy and safety. [less ▲]

Detailed reference viewed: 25 (3 ULg)
Full Text
See detailRapport d'activité semestriel n°3
Legrand, Catherine ULg; Henrotin, Yves ULg

Report (2016)

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailReview of soluble biomarkers of osteoarthritis: lessons from animal model
Legrand, Catherine ULg; Lambert, Cécile ULg; Comblain, Fanny ULg et al

in Osteoarthritis and Cartilage (2016, April), 24(suppl 1), 88

Detailed reference viewed: 35 (8 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritic sclerotic subchondral osteoblasts secreted elevated concentration of fibulin-3 fragments in vitro
Sanchez, Christelle ULg; Lambert, Cécile ULg; Comblain, Fanny ULg et al

in Osteoarthritis and Cartilage (2016, April), 24(suppl 1), 83

Detailed reference viewed: 25 (6 ULg)
Full Text
Peer Reviewed
See detailFibulin-3 fragments are prognostic biomarkers of osteoarthritis incidence in overweight and obese women
Runhaar, Jos; Sanchez, Christelle ULg; Taralla, Sébastien et al

in Osteoarthritis Cartilage (2016), 24(4), 672-678

OBJECTIVE: To determine the association between three fibulin-3 peptides and the incidence of radiographic and clinical knee osteoarthritis (OA). DESIGN: Women between 50 and 60 years, with a BMI >/=27 kg ... [more ▼]

OBJECTIVE: To determine the association between three fibulin-3 peptides and the incidence of radiographic and clinical knee osteoarthritis (OA). DESIGN: Women between 50 and 60 years, with a BMI >/=27 kg/m2, free of knee OA, were recruited. Using binary logistic regression, the association between baseline concentration of serum fibulin (Fib)3-1, Fib3-2 and Fib3-3 and incidence of clinical and radiographic knee OA after 30 months of follow-up was evaluated. RESULTS: Baseline and follow-up measurements were available for 241 women with a mean age of 55.9 +/- 3.2 years and mean BMI of 31.7 +/- 3.6 kg/m2. None of the concentrations of the three Fib3 epitopes were associated with the incidence of medial or lateral joint space narrowing (JSN) >/=1.0 mm or the incidence of Kellgren & Lawrence (K&L) grade >/=2 after 30 months. All three Fib3 epitopes were associated with the incidence of the clinical and radiographic ACR-criteria and Fib3-1 and Fib3-3 also with chronic pain at follow-up. When adjusted for the other Fib3 peptide concentrations, only Fib3-1 was significantly associated to the incidence of the American College of Rheumatology (ACR)-criteria (OR 3.2 [1.2-8.7]) and chronic pain at follow-up (OR 3.0 [1.2-7.7]). CONCLUSIONS: Baseline fibulin-3 concentrations are associated with the incidence of clinical knee OA among middle-aged overweight and obese women. Therewith, they meet the criteria of a prognostic biomarker according to the BIPED biomarker classification for OA. Further validation of the fibulin-3 epitopes seems warranted in order to better distinguish subgroups of individuals at increased risk for knee OA development. [less ▲]

Detailed reference viewed: 21 (4 ULg)
Full Text
See detailBien soigner l'arthrose: un enjeu de société
Henrotin, Yves ULg

Conference (2016, February 04)

Detailed reference viewed: 51 (1 ULg)
Full Text
See detailDes champignons contre l'arthrose
Henrotin, Yves ULg; Oprenyeszk, Frédéric ULg

Article for general public (2016)

Detailed reference viewed: 25 (2 ULg)
Full Text
See detailGuérir l'arthrose grâce au champignon de Paris
Henrotin, Yves ULg; Oprenyeszk, Frédéric ULg

Article for general public (2016)

Detailed reference viewed: 25 (0 ULg)
Full Text
See detailBiomarqueurs dans l'arthrose et acide hyaluronique
Henrotin, Yves ULg

Conference (2016, January 16)

Detailed reference viewed: 30 (2 ULg)
Full Text
See detailBien soigner l'arthrose: un enjeu capital pour notre société!
Henrotin, Yves ULg

Conference (2016, January 07)

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailTechniques de réhabilitation abdominale et spinale pour le patient lombalgique
Demoulin, Christophe ULg; Vanderthommen, Marc ULg; GROSDENT, Stéphanie ULg et al

in EMC - Kinésithérapie-Médecine physique-Réadaptation (2016)

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailThe need for predictive, prognostic, objective and complementary blood-based biomarkers in osteoarthritis (OA)
Bay-Jensen, Anne-Christine; Henrotin, Yves ULg; Karsdal, Morten et al

in Ebiomedicine (2016)

Detailed reference viewed: 22 (5 ULg)
Full Text
Peer Reviewed
See detailLes croyances délétères des patients lombalgiques : revue narrative de la littérature
Demoulin, Christophe ULg; Roussel, Nathalie; Marty, Marc et al

in Revue Médicale de Liège (2016), 71(1), 40-46

Detailed reference viewed: 252 (25 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria.
Bay-Jensen, A. C.; Reker, D.; Kjelgaard-Petersen, C. F. et al

in Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society (2016), 24(1), 9-20

OBJECTIVE: To review and summarize biomarker data published from April 2014 to May 2015 to provide insight to the ongoing work in the field of osteoarthritis (OA). Furthermore, to summarize the BIPED ... [more ▼]

OBJECTIVE: To review and summarize biomarker data published from April 2014 to May 2015 to provide insight to the ongoing work in the field of osteoarthritis (OA). Furthermore, to summarize the BIPED criteria and set it in context of the medical needs of 2015. METHODS: PubMed was used as searching machine: Time period 2014/04/01-2015/05/01, MeSH term [Biomarker] AND [Osteoarthritis], Language; English, Full text available. Reviews were excluded. Only papers describing protein based biomarkers measured in human body fluids from OA patients were included. RESULTS: Biomarkers of joint tissue turnover, cytokines, chemokines and peptide arrays were measured in different cohorts and studies. Amongst those were previously tested biomarkers such as osteocalcin, Carboxy-terminal cross-linked fragment of type II collagen (CTX-II) and cartilage oligomeric matrix protein (COMP). A majority of the biomarker were classified as I, B or B biomarkers according to the BIPED criteria. Work is continuing on testing biomarkers in OA. There is still a huge, unmet medical need to identify, test, validate and qualify novel and well-known biomarkers. A pre-requisite for this is better characterization and classification of biomarkers to their needs, which may not be reached before higher understanding of OA phenotypes has been gained. In addition, we provide some references to some recent guidelines from Food and Drug Administration (FDA) and European Medicines Agency (EMA) on qualification and usage of biomarkers for drug development and personalized medicine, which may provide value to the field. [less ▲]

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailOsteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives.
Henrotin, Yves ULg; Sanchez, Christelle ULg; Bay-Jensen, A. C. et al

in Annals of physical and rehabilitation medicine (2016)

Specific soluble biomarkers can be powerful tools for the diagnosis, prognosis and personalized management of osteoarthritis (OA). Biomarkers are potential indicators of the effect of a drug on cartilage ... [more ▼]

Specific soluble biomarkers can be powerful tools for the diagnosis, prognosis and personalized management of osteoarthritis (OA). Biomarkers are potential indicators of the effect of a drug on cartilage metabolism and provide crucial information about the mechanisms of drug action. In this review, we address key questions concerning the use of biomarkers in OA management: Why do we need soluble biomarkers? What are the most widely investigated biomarkers derived from cartilage extracellular matrix? What are the most common pitfalls in interpreting soluble biomarker measurements? What are the perspectives and future research directions in this field? We review current evidence to propose that cartilage-derived soluble biomarkers are complementary "drug development tools" that can be applied during drug development from preclinical research to clinical evaluation. In the future, such biomarkers could be surrogate markers of clinical and/or imaging outcomes. Successful standardization and implementation of automated biomarker assays will facilitate their use in companion diagnostics in the context of personalized medicine for enhanced management of OA. [less ▲]

Detailed reference viewed: 18 (1 ULg)
Full Text
Peer Reviewed
See detailReview of dietary supplements for the management of osteoarthritis in dogs in studies from 2004 to 2014
Comblain, Fanny ULg; Serisier, Samuel; Barthelemy, Nicolas ULg et al

in Journal of Veterinary Pharmacology & Therapeutics (2016), 39

Detailed reference viewed: 144 (8 ULg)
Full Text
Peer Reviewed
See detailCombined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib
Hochberg, M. C.; Martel-Pelletier, J.; Monfort, J. et al

in Ann Rheum Dis (2016), 75(1), 37-44

OBJECTIVES: To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. METHODS: Double-blind ... [more ▼]

OBJECTIVES: To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain. METHODS: Double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score >/=301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D. RESULTS: The adjusted mean change (95% CI) in WOMAC pain was -185.7 (-200.3 to -171.1) (50.1% decrease) with CS+GH and -186.8 (-201.7 to -171.9) (50.2% decrease) with celecoxib, meeting the non-inferiority margin of -40: -1.11 (-22.0 to 19.8; p=0.92). All sensitivity analyses were consistent with that result. At 6 months, 79.7% of patients in the combination group and 79.2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups. CONCLUSIONS: CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile. TRIAL REGISTRATION NUMBER: NCT01425853. [less ▲]

Detailed reference viewed: 19 (0 ULg)